Recruiting

EMSELLA

Sponsor:

San Diego Sexual Medicine

Code:

NCT03877640

Conditions

Stress Urinary Incontinence

Urge Incontinence

Eligibility Criteria

Sex: Female

Age: 21 - 70+

Healthy Volunteers: Not accepted

Interventions

BTL EMSELLA

Study Details

Brief summary:

The purpose of this prospective study is to examine the safety and efficacy of high intensity focused electromagnetic (HIFEM) technology for the treatment of women with stress urinary incontinence (SUI), urge incontinence (UI) and mixed stress urinary and urge incontinence (MUI), looking at any potential sexual health benefits that may be concomitantly achieved from this treatment.

Conditions

Stress Urinary Incontinence

Urge Incontinence

Study ID

NCT03877640

Start date

Jan 11, 2019

Status verified date

Oct, 2023

Completion date

Jun, 2024

Anticipated

Primary completion date

Jun, 2024

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 21 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Subject provides written informed consent and HIPAA authorization before any study procedures are conducted;
2. Subject is female;
3. Subject is aged 21-80 years;
4. Subject has a body mass index (BMI) < 37 kg/m2;
5. Subject has stress urinary incontinence, urge incontinence, or mixed urinary incontinence as determined by the QUID;
6. Subject is currently sexually active and willing to continue sexual activity throughout the study;
7. Subject is willing to continue level of core exercise currently being performed or not performed during the study (e.g. gym, Pilates, yoga);
8. Subject is willing to maintain her current prescription and over the counter medications throughout the study without changing them;
9. Subject agrees to comply with the study procedures and visits.

Exclusion Criteria:

1. Subject has used the BTL EMSELLA device previously;
2. Subject has any significant pelvic organ prolapse;
3. Subject has clinically significant findings on physical examination;
4. Subject has any chronic medical condition (e.g. neurologic disorder) or psychologic disorder that the Principal Investigator feels makes her ineligible for the study;
5. Subject is unwilling to maintain current level of exercise throughout the study;
6. Subject has been diagnosed with overactive bladder or interstitial cystitis;
7. Subject experiences bladder pain or scores above 0 on the pain questions on the O'Leary/Sant Voiding and Pain Indices (ICSI/ICPI);
8. Subject experiences pain with sexual activity
9. Subject answers anything other than "almost never or never" or "a few times" on pain questions 17 or 18 of the Female Sexual Function Index (FSFI)
10. Subject answers anything other than "very low or none at all" or "low" on pain questions 19 of the (FSFI)
11. Subject planning to have surgery during the study;
12. Subject has untreated malignancy;
13. Subject is pregnant, planning to get pregnant or within 3 months postpartum;
14. Subject has a pacemaker;
15. Subject has and implant or IUD containing metal (e.g. copper 7);
16. Subject has piercing between the waist and knees and is not willing to remove it before each treatment;
17. Subject has a history of substance abuse within 12 months prior, or consuming > 14 alcoholic drinks per week;
18. Subject has received an investigational drug within 30 days prior to signing consent;
19. Subject has any condition or exhibits behavior that indicates to the Principal Investigator that the Subject is unlikely to be compliant with study procedures and visits.

Study Design

Enrollment

21 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Active EMSELLA treatment

6 treatments on the BTL EMSELLA using a device protocol that is active HIFEM technology

sham comparator: Sham EMSELLA treatment

6 treatments on the BTL EMSELLA with a sham device protocol that provides some sensation without active HIFEM technology

Interventions

BTL EMSELLA

High intensity focused electromagnetic (HIFEM) technology induces deep pelvic floor muscle contractions designed to deliver the equivalent of 11,200 Kegel exercises over 28 minutes.

Primary outcome measure

  • Incidence of Treatment-Emergent Adverse Events [ Time Frame: Up to 18 weeks for active arm; up to 32 weeks for sham arm ]
  • QUID (Questionnaire for Urinary Incontinence Diagnosis) [ Time Frame: At screen, 4 weeks, 6 weeks, 10 weeks, 18 weeks; for sham arm additionally at 20 weeks, 24 weeks, 32 weeks ]

Central Contacts and Locations

Central contacts

Clinical Research Manager

619-265-8865information@sdsm.info

Locations

San Diego Sexual Medicine

Recruiting

San Diego, California, United States, 92120

Contacts

Clinical Research Manager

619-265-8865information@sdsm.info

Principal Investigator:

Irwin Goldstein, MD

More Information

Sponsor

San Diego Sexual Medicine

Last update posted

Oct 10, 2023

Last verified

Oct, 2023

Keywords

  • incontinence
  • stress urgency incontinence
  • urge incontinence
  • EMSELLA

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by San Diego Sexual Medicine on 2023-10-10.